Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of AER-01 in Healthy Volunteers and COPD
NCT05862623Phase 1Unknown
- Sponsor
- Aer Therapeutics
- Start
- May 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing AER-01 with Placebo (2 arms). Primary endpoint: Number of participants with treatment-related adverse events at Day 8. Status: unknown.
02
Drugs
fexlamose
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05862623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05862623.